4basebioLSE:4BB 61 EBITDA Margin % is -1,606.94% as of Dec. 2025. GuruFocus rates LSE:4BB with a GF Score™ of 61/100 and a GF Value™ of £28.18 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 944 Biotechnology companies, 4basebio ranks worse than 78.71% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. 4basebio's EBITDA for the
six
months ended in Dec. 2025 was £-8.34 Mil. 4basebio's Revenue for the
six
months ended in Dec. 2025 was £0.52 Mil. Therefore, 4basebio's EBITDA margin for the quarter that ended in Dec. 2025 was -1,606.94%.
4basebio (LSE:4BB) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
4basebio EBITDA Margin % Related Terms
4basebio EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for 4basebio's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:4BB vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, 4basebio's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
4basebio EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 4basebio's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where 4basebio's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
4basebio (LSE:4BB) has a EBITDA Margin % of -1,606.94% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on 4basebio and its competitors. According to the industry distribution chart, 4basebio ranks #743 out of 944 companies in the Biotechnology industry, placing it in the top 78.7%.
Is 4basebio's EBITDA Margin % too high?
4basebio's current EBITDA Margin % is -1,606.94%. Based on the distribution chart, 4basebio ranks #743 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, 4basebio has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does 4basebio's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, 4basebio ranks #743 out of 944 companies for EBITDA Margin %. This places 4basebio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on 4basebio and its competitors. 4basebio's current EBITDA Margin % is -1,606.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4basebio stock overvalued right now?
Based on GuruFocus' analysis, 4basebio (LSE:4BB) is currently considered Possible Value Trap. The stock's GF Value™ is £28.18, compared to a current price of £5.25 — trading 81.4% below its estimated fair value. The current EBITDA Margin % is -1,606.94%. 4basebio's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For 4basebio (LSE:4BB), the current EBITDA Margin % is -1,606.94% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 4basebio (LSE:4BB) Overvalued in 2026?
Based on GuruFocus' analysis, 4basebio stock appears to be undervalued.
The current stock price of £5.25 is trading 81.4% below its estimated GF Value™ of £28.18.
GuruFocus considers 4basebio to be Possible Value Trap.
Key valuation signals for LSE:4BB:
EBITDA Margin %: -1,606.94%
GF Value™: £28.18 vs. price of £5.25 (81.4% below fair value)
No single metric tells the full story. See the LSE:4BB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effectively and safely delivering these DNA-based products to patients. The company operates across three geographic segments: Europe, the United States, and the Rest of the World, with the majority of its revenue generated from the United States.
61GF Score
Get the complete analysis for LSE:4BB
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:4BB has been successfully added to your 
